CN106902120A - Citric acid support method replaces application of the cloth in Senile Degenerative Cardiac Valvular Diseases adjuvant therapy medicaments - Google Patents
Citric acid support method replaces application of the cloth in Senile Degenerative Cardiac Valvular Diseases adjuvant therapy medicaments Download PDFInfo
- Publication number
- CN106902120A CN106902120A CN201510968845.4A CN201510968845A CN106902120A CN 106902120 A CN106902120 A CN 106902120A CN 201510968845 A CN201510968845 A CN 201510968845A CN 106902120 A CN106902120 A CN 106902120A
- Authority
- CN
- China
- Prior art keywords
- cloth
- support method
- citric acid
- acid support
- cardiac valvular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a kind of new application of medicine, specifically ask method for cloth to the auxiliary therapeutic action of Senile Degenerative Cardiac Valvular Diseases.The clinical experimental study that the present invention is carried out shows, while conventional therapy is carried out to Senile Degenerative Cardiac Valvular Diseases patient, give support method carries out auxiliary treatment for cloth, Senile Degenerative Cardiac Valvular Diseases patient lungs' extravasated blood can significantly be treated, the symptom of pleural effusion, is effectively improved the various arrhythmia cordis such as auricular fibrillation, atrium and ventricular hypertrophy, the recurrence rate again of disease can be reduced, the quality of life of patient is improved.
Description
Technical field
The present invention relates to a kind of new application of medicine, specifically citric acid support method replaces application of the cloth in Senile Degenerative Cardiac Valvular Diseases adjuvant therapy medicaments.
Background technology
Senile Degenerative Cardiac Valvular Diseases（senile degenerative heart valvular diease, SDHVD）It is also called old Calcified heart film valve disease, Aged Heart calcification syndrome.This disease refers to original normal film valve, or on the basis of having a slight valve abnormalities, with advancing age, there is retrogression in heart valve connective tissue, fibrosis, thicken and calcification, so as to cause the dysfunction of valve and support, to invade based on aorta petal and annulus of mitral valve, mainly there is Calcified active film valve narrow and incompetence, annulus of mitral valve and calcification of mitral valve, and the type such as the simultaneous joint valvular calcification of two valves, cause hemodynamic responses when serious, Aged Heart Failure is turned into, arrhythmia cordis, faint and die suddenly one of the main reasons.With crowd's life-time dilatation, the disease has become the financial burden heavy with society of personal, family.
The colloid fiber and elastomer that SDHVD pathology is mainly valve increase, and fracture, decomposition, elastic fibers dyeing gradually occur irregularly, heart valve such as anterior mitral valve ventricular side visible lipid striped of being grown up, and with age, fatty streaks also increase.Being related to pathogenesis at present has mechanical pressure theory, calcareous abnormal deposition, atherosclerosis, Apoptosis, the reduction of alkaline phosphatase enzyme bioactivity, dyslipidemias precipitation etc..
Effective drug therapy is there is no to SDHVD now, for the disease treatment according to the course of disease, stadium it is different and different.The patient of clinical symptoms is normally there is no for heart function carries out follow-up, need not typically treat；To the patient with high risk factors such as atherosclerosis, or merge and induce the sick related diseases, such as hypertension, coronary heart disease, the patient of diabetes and typically take pharmaceutical intervention, such as statin and ACEI class medicines；General the taking of patient for having there are clinical symptoms carries out drug therapy to complication, and severe patient uses surgical operation or the method for PCI.Clinically used at present, although the percutaneous aortic valve Balloon Angioplasty expense for substituting aortic valve replacement is low, operation risk is small, but long-term effect is poor, therefore needing a kind of patient of medicine for treating SDHVD to there are clinical symptoms badly carries out effective treatment.
The content of the invention
For above-mentioned problem, the present invention provides citric acid support method and replaces a kind of new medical usage of cloth, i.e., as the application of the sick adjuvant therapy medicaments of Senile degenerative heart film valve.
Citric acid support method of the present invention is for the pharmaceutical composition that cloth is containing citric acid support method for cloth.
Citric acid support method of the invention for cloth composition contain therapeutically effective amount, as the citric acid support method of active component for cloth available auxiliary material, usually oral administration.
The citric acid support method of oral administration of the present invention is for the capsule or coating tablet that cloth is with fast release micropill as content.
The present invention is also further studied support method for cloth as the possibility mechanism of the adjuvant therapy medicaments of Senile degenerative heart film valve disease：Citric acid support method is EGFR-TK for cloth（JAK）Inhibitor, can mediate downstream apoptosis and signal transduction and activation sub 3（STAT3）The activation of path.And JAK/STAT3 paths are a kind of Cellular Signaling Transduction Mediated paths, it is related to various pathophysiological processes such as cell proliferation and differentiation, Apoptosis, inflammation, tumour.It is presumed that, citric acid support method, by suppressing JAK paths, by the STAT3 of mediate downstream, participates in lowering angiogenesis factor for cloth（VEGF）Reduce the generation of new vessels; reducing new vessels promotes film valve enchondral ossification to form the risk of calcification; so as to significantly improve the retrogression of patient's heart valve connective tissue; fibrosis, thickens and calcification, protects cardiac muscle cell; the long-term effect of operative treatment is maintained, the risk that heart failure occurs is reduced.
Specific embodiment
With specific embodiment, the present invention is further described below.
The citric acid support method of embodiment 1 is for cloth to the auxiliary therapeutic action of Senile Degenerative Cardiac Valvular Diseases patient
1st, data and method
1.1 experimental subjects and packet
By 69 SDHVD patients（Diagnostic criteria is：Aorta petal and mitral valve or annulus are thickened, calcification, reflection enhancement, regular edges, mobility reduction；X ray examinations find that aorta petal or bicuspid valve have calcification shadow；More than two grades systolic murmurs are heard in aortic area or have diastolic murmur concurrently, or noise is heard in aortic area and mitral area.）Observation group 39 and control group 30 are randomly divided into, two groups of sexes and the state of an illness are statistically analyzed, and there was no significant difference（p>0.05）, with comparativity.
1.2 treatment methods
Observation group and the equal active treatment complication of control group patient, actively give foxalin piece to the patient with heart failure, arrhythmia cordis first（Orally, 0.05~0.1mg is given within every 6~8 hours, maintenance dose is daily 0.05~0.1mg）, diuretics FUSAIMI PIAN（One time a day, each 40mg）, cardiotonic digoxin（One time a day, each 0.25mg）, beta-blocker Pu Lailuoer pieces（3 times a day, each 30mg）Deng symptomatic treatment；Additionally, all observation groups and control group patients received oral's sulfuric acid ointment element A, 3 times a day, each 0.3g, is within 3 months a course for the treatment of to block deposition of the calcium on vascular wall.While observation group receives above-mentioned treatment, citric acid support method is given for pieces of cloth, 2 times a day, each 5mg.It is within 3 months a course for the treatment of.
1.3 observation index and method
It is effective：The symptom such as heart failure or arrhythmia cordis, expiratory dyspnea is substantially less or disappears, than reducing by 75% or so before treatment.Check echocardiogram shows that the chamber radial line of heart is significantly reduced before relatively treating, and cardiac size is returned to normal.Effectively：The symptom such as heart failure or arrhythmia cordis, expiratory dyspnea has mitigated, than reducing by 50% or so before treatment.Echocardiogram shows that chamber radial line has been reduced, and cardiac size has recovered, but degree is not as good as effective.It is invalid：Symptom without improvement or treatment during aggravated or dead.Total effective rate is effective number, and efficiently individual quantity sum accounts for this group of percentage of total number of persons.
1.4 statistical methods
Statistical procedures are carried out using SPSS13.0, enumeration data are checked using t,p<0.05 is that difference is statistically significant.
2nd, result
2.1 curative effects
After one course for the treatment of of treatment, effective 19 of observation group, effective 15, invalid 5, total effective rate 87%；Effective 10 of observation group, effective 11, no effect 9, total effective rate 70%；Observation group's total effective rate is significantly higher than control group,p＜ 0.05.
1 two groups of therapeutic effects of table compare
| Group | Total number of persons（n） | It is effective（n） | Effectively（n） | It is invalid（n） | Total effective rate（%） |
| Observation group | 39 | 19 | 15 | 5 | 87% |
| Control group | 30 | 10 | 11 | 9 | 70% |
Note：p＜ 0.05
2.2 prognosis
Observation group patient is taken a turn for the better through treatment and leaves hospital 27, and control group patient is taken a turn for the better after treatment and leaves hospital 15, and two groups of discharged patients are carried out with the follow-up of a year by a definite date, and there are 2 patient's compound hospitalizations again, recurrence rate 7.4% in treatment group；6 patient's hospitalizations again of control group, recurrence rate is 40%, and control group Patients on Recurrence rate is apparently higher than control group.
3rd, conclusion
While routine medication is carried out to SDHVD patient, give citric acid support method carries out auxiliary treatment for cloth, the symptom such as heart failure or arrhythmia cordis, expiratory dyspnea can be significantly improved, reduce the generation of heart failure and arrhythmic events, the recurrence rate again of SDHVD is effectively reduced, the life quality of patient is improved.
Claims (5)
1. citric acid support method replaces the application of cloth or its composition in Senile Degenerative Cardiac Valvular Diseases adjuvant therapy medicaments.
2. application according to claim 1, it is characterised in that described citric acid support method is for the pharmaceutical composition that cloth is containing citric acid support method for cloth.
3. application according to claim 2, it is characterised in that described citric acid support method replaces cloth and pharmaceutically acceptable auxiliaries for the citric acid support method as active component that cloth pharmaceutical composition contains therapeutically effective amount.
4. application according to claim 1 and 2, it is characterised in that its method of administration is oral administration.
5. application according to claim 4, it is characterised in that citric acid support method is made with capsule or coating tablet that fast release micropill is main content for cloth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510968845.4A CN106902120B (en) | 2015-12-22 | 2015-12-22 | Application of tofacitinib citrate in auxiliary treatment medicine for senile degenerative heart valve disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510968845.4A CN106902120B (en) | 2015-12-22 | 2015-12-22 | Application of tofacitinib citrate in auxiliary treatment medicine for senile degenerative heart valve disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106902120A true CN106902120A (en) | 2017-06-30 |
| CN106902120B CN106902120B (en) | 2019-12-27 |
Family
ID=59199581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510968845.4A Active CN106902120B (en) | 2015-12-22 | 2015-12-22 | Application of tofacitinib citrate in auxiliary treatment medicine for senile degenerative heart valve disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106902120B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110327346A (en) * | 2019-06-27 | 2019-10-15 | 慧生医学科技(徐州)有限公司 | Ba Ruike is preparing the application in the drug for treating characteristics of calcific valvular heart disease for Buddhist nun |
| CN112957362A (en) * | 2021-04-30 | 2021-06-15 | 复旦大学附属中山医院 | Application of tofacitinib citrate in preparation of medicine for treating myocarditis related to immune checkpoint inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303563A1 (en) * | 2011-11-10 | 2013-11-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using jak inhibitors |
-
2015
- 2015-12-22 CN CN201510968845.4A patent/CN106902120B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303563A1 (en) * | 2011-11-10 | 2013-11-14 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using jak inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| 余雄伟，等: ""JAK/STAT信号通路与组织器官纤维化的相关性研究进展"", 《新医学》 * |
| 李婉秋: "心血管疾病中JAK-STAT通路研究进展", 《昆明医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110327346A (en) * | 2019-06-27 | 2019-10-15 | 慧生医学科技(徐州)有限公司 | Ba Ruike is preparing the application in the drug for treating characteristics of calcific valvular heart disease for Buddhist nun |
| CN112957362A (en) * | 2021-04-30 | 2021-06-15 | 复旦大学附属中山医院 | Application of tofacitinib citrate in preparation of medicine for treating myocarditis related to immune checkpoint inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106902120B (en) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mouillet et al. | Outcomes following pacemaker implantation after transcatheter aortic valve implantation with C ore V alve® devices: Results from the FRANCE 2 R egistry | |
| WO2021189753A1 (en) | Pharmaceutical composition for strengthening body and treating lung diseases and application thereof | |
| Li et al. | Takotsubo's syndrome after mitral valve repair and rescue with extracorporeal membrane oxygenation | |
| CN106902120A (en) | Citric acid support method replaces application of the cloth in Senile Degenerative Cardiac Valvular Diseases adjuvant therapy medicaments | |
| Ashrafian et al. | Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint | |
| KR20230106644A (en) | How to Treat Conditions Associated with the S1P1 Receptor | |
| Chakrabortty et al. | Nintedanib in the management of pulmonary fibrosis after COVID-19: a case report | |
| EP3616697B1 (en) | Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition comprising berberine and oryzanol | |
| CN115414325A (en) | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof | |
| CN109692283A (en) | Chinese medicine composition, the drug comprising Chinese medicine composition and preparation method and application | |
| CN106902119B (en) | Application of tofacitinib citrate in medicine for treating multiple Takayasu arteritis | |
| Gupta et al. | Diabetes and the Heart: Coronary Artery Disease | |
| Różewicz-Juraszek et al. | Case report on aortic valve replacement in adult woman with systemic mastocytosis (RCD code: VIII) | |
| Musiał et al. | Local anaesthesia with analgosedation in patients qualified for transcatheter aortic valve implantation (TAVI): first institute’s results and experiments | |
| Muraleedharan et al. | Lachesis mutus and Calendula officinalis Q in Diabetic Foot Ulcer Treatment–Two Case Reports | |
| CN108421020A (en) | It is a kind of to be used to treat Ginger P.E of diabetic retinopathy and its preparation method and application | |
| CN101411764A (en) | Use of Chinese medicinal composition in preparing medicament for treating degenerative cardiac valve disease of old age | |
| RU2760090C1 (en) | Method for treating postcovid syndrome by alloplant biomaterial | |
| CN109718230A (en) | Application of the salviandic acid A in preparation inhibiting hyperuricemia and anti-gout drugs | |
| ZAIDI et al. | SINGLE-BLIND, RANDOMIZED, CONTROL TRIAL OF A UNANI COMPOUND FORMULATION IN ILTEHAB TAJAWEEFE ANAF MUZMIN | |
| EP3730147A1 (en) | Preparation with hypoglycemic effect | |
| Dalvi et al. | INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES | |
| Abeysuriya et al. | Outcome of patients with ST segment elevation myocardial infarction (STEMI) following percutaneous transluminal coronary angioplasty: a retrospective study | |
| CN107252442B (en) | Application of the Radix Salviae Miltiorrhizae side of promoting blood circulation in terms of anti-senile aortic valve calcification | |
| Xiong | A Review of Takotsubo Cardiomyopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Co-patentee after: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP CO.,LTD. Address before: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee before: Jiangsu Wan Bang Biochemical Medicine Co.,Ltd. Address after: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Co-patentee after: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee after: Jiangsu Wan Bang Biochemical Medicine Co.,Ltd. Address before: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee before: JIANGSU WANBANG BIOPHARMACEUTICALS Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200515 Address after: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP CO.,LTD. Address before: 221004 No. 6, Yang Shan Road, Jinshan Economic Development Zone, Jiangsu, Xuzhou Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., Ltd. Patentee before: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP Co.,Ltd. |
|
| TR01 | Transfer of patent right |